Filing Details

Accession Number:
0001415889-24-017005
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-06-14 18:01:49
Reporting Period:
2024-06-12
Accepted Time:
2024-06-14 18:01:49
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1815442 Kymera Therapeutics Inc. KYMR () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1451612 Bruce Booth C/O Kymera Therapeutics, Inc.
200 Arsenal Yards Blvd., Suite 230
Watertown MA 02472
No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2024-06-12 11,838 $35.35 4,558,827 No 4 S Indirect See footnote
Common Stock Disposition 2024-06-12 1,997 $36.02 4,556,830 No 4 S Indirect See footnote
Common Stock Disposition 2024-06-12 2,485 $35.35 804,212 No 4 S Indirect See footnote
Common Stock Disposition 2024-06-12 420 $36.02 803,792 No 4 S Indirect See footnote
Common Stock Disposition 2024-06-13 8,430 $34.98 4,548,400 No 4 S Indirect See footnote
Common Stock Disposition 2024-06-13 1,770 $34.98 802,022 No 4 S Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 S Indirect See footnote
Footnotes
  1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. on January 22, 2024.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.95 to $35.88 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4) and (7).
  3. These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extend of his pecuniary interest therein, if any.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.99 to $36.29 inclusive.
  5. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 22, 2024.
  6. The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any.
  7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.95 to $34.985 inclusive.